Engineering ex vivo T-cell expansion for CAR-T therapy: bridging biological fidelity and bioprocess scalability through platforms, functional consumables, and integrated closed manufacturing.

Journal: Frontiers in immunology •

Abstract

Abstract text is not embedded in this discovery record. Please consult the full-text publication via the source link on the right.

Subjects & Keywords

How to Cite this Article

Wu Q, Jiang M, Li Y, et al. (2026). "Engineering ex vivo T-cell expansion for CAR-T therapy: bridging biological fidelity and bioprocess scalability through platforms, functional consumables, and integrated closed manufacturing.". Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1981337